Form D · Biotechnology
Allogene Therapeutics, Inc.
South San Francisco, CA · CIK 0001737287
Offering snapshot reported Apr 19, 2018 · SEC filing
- Reported sold
- $412M Offering amount: $412M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 6, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 19, 2018 | Initial | $411,770,409 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-310557
The consideration for $111,770,405 of the total offering amount was non-cash consideration, and the consideration for $150,000,002 of the total offering amount was capital commitments.
Source: Form D, filed Apr 19, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Abraham | Director |
| Arie Belldegrun | Director |
| David Bonderman | Director |
| David Chang | Director |
| John Deyoung | Director |
| Franz Humer | Director |
| Joshua A. Kazam | Director, Executive |
| Todd Sisitsky | Director |
| David M. Tanen | Executive |
| Owen Witte | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
270 Littlefield Ave
South San Francisco, CA, 94080
South San Francisco, CA, 94080